• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TLX

    Telix Pharmaceuticals Limited

    Subscribe to $TLX
    $TLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Telix Pharmaceuticals Limited

    DatePrice TargetRatingAnalyst
    7/3/2025$23.00Buy
    H.C. Wainwright
    6/5/2025$22.00Outperform
    Wedbush
    11/15/2024$21.00Buy
    UBS
    See more ratings

    Telix Pharmaceuticals Limited Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Telix Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $23.00

      7/3/25 7:52:31 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Telix Pharmaceuticals with a new price target

      Wedbush initiated coverage of Telix Pharmaceuticals with a rating of Outperform and set a new price target of $22.00

      6/5/25 7:35:43 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Telix Pharmaceuticals with a new price target

      UBS initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $21.00

      11/15/24 8:23:07 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Telix Pharmaceuticals Limited Press Releases

    Fastest customizable press release news feed in the world

    See more

    Telix Pharmaceuticals Limited SEC Filings

    See more
    • Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

      MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for

      6/23/25 7:15:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Precision Medicine Announces AlFluor Radiochemistry Platform

      MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces it has launched a novel PET1 radiochemistry solution based on 18F-aluminium fluoride (AlF), named AlFluor™. The AlFluor™ platform technology enables flexible radiolabeling of PSMA2 with either AlF or gallium-68 (68Ga). It also has the potential to be used with ligands targeting NETs3 and FAP4, as well as other novel imaging agents under development by Telix and its strategic partners. Developed to combine the imaging benefits of 18F with the convenience of 68Ga kit-based workflows, the AlFluor™ platform supports both centr

      6/20/25 8:00:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

      MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24. Presentation highlights include the ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer, preclinical data on Telix's TLX252 alpha therapy candidate in CAIX1 -expressing tumors in combination with DDRIs2, and clinical study data on Illuccix

      6/19/25 8:18:38 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.

      MELBOURNE, Australia and INDIANAPOLIS, June 11, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces that its next-generation PSMA-PET imaging1 agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United States (U.S.). Gozellix is available through Telix's comprehensive network of distribution partners, Cardinal Health, Inc., PharmaLogic Holdings Corp., Jubilant Radiopharma, and RLS Radiopharmacies. After radiolabelling with 68Ga, Gozellix is indicated for PET2 scanning of PSMA3 positive lesions in men with prostate

      6/11/25 7:00:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

      MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET. This education session will focus on the growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals. The following key opinion leaders will provide their perspectives on the clinical utility and opportunity for Telix's theranostic candidates. Prostate cancer therapy (TLX591): Oliver S

      6/3/25 6:57:12 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix to Host Investor Day in New York City on June 11, 2025

      MELBOURNE, Australia and INDIANAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces it will host an Investor Day on Wednesday, June 11, 2025, in person, in New York City, from 8:30am ET to 12.00pm ET. Institutional investors, analysts and company guests are cordially invited to attend the session, which will focus on the growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals. Members of the Telix leadership team will present at the event, including Managing Director and Group CEO, Dr. Christian Behrenbruch; Group Chief Medical Officer,

      5/22/25 8:00:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

      MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in aggressive, radioiodine-resistant (RAI-R) thyroid cancer1. TLX400 (177Lu-DOTAGA.Glu.(FAPi)2) has been in-licensed by Telix as part of a portfolio of next-generation therapeutic and diagnostic ("theranostic") radiopharmaceutical candidates2. TLX400 has potential clinical utility in several on

      5/7/25 4:13:48 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix's Illuccix PSMA-PET Imaging Agent Approved in France

      MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in France by ANSM2 for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinica

      4/28/25 6:30:32 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Reports US$186M Q1 Revenue, Up 62% YOY

      MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). All figures are in $US unless stated otherwise. Strong Q1 2025 revenue growth Q1 2025 unaudited revenue of approximately $186 million represents an increase of 62% over the prior year corresponding quarter (Q1 2024: $115M) and a quarter-over-quarter increase of 31% (Q4 2024: $142 million) and includes: $151 million from global sales of Illuccix®, up 35% over the prior year corresponding quarter (Q1 2024: $112 million

      4/22/25 4:17:09 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

      MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study2. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma

      4/15/25 6:37:04 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      6/11/25 5:09:40 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      5/21/25 8:39:11 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      4/28/25 6:37:46 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      4/22/25 5:06:14 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      4/17/25 4:39:47 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      4/17/25 8:37:27 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      4/7/25 7:37:22 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      3/18/25 4:28:18 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      3/12/25 8:13:37 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      2/26/25 7:34:54 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Telix Pharmaceuticals Limited Leadership Updates

    Live Leadership Updates

    See more
    • Telix Appoints Paul Schaffer as Chief Technology Officer

      MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada's particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotr

      4/7/25 6:30:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anne Whitaker Appointed as Non-Executive Director

      MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

      4/3/25 6:13:56 PM ET
      $ICLR
      $TLX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

      MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities1. This transaction delivers a pipeline of drug candidates against validated cancer targets including DLL32 and integrin αvβ63, as well as a panel of other agents against novel targets in early discovery stage.

      1/30/25 4:57:53 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Telix Pharmaceuticals Limited Financials

    Live finance-specific insights

    See more
    • Telix Reports US$186M Q1 Revenue, Up 62% YOY

      MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). All figures are in $US unless stated otherwise. Strong Q1 2025 revenue growth Q1 2025 unaudited revenue of approximately $186 million represents an increase of 62% over the prior year corresponding quarter (Q1 2024: $115M) and a quarter-over-quarter increase of 31% (Q4 2024: $142 million) and includes: $151 million from global sales of Illuccix®, up 35% over the prior year corresponding quarter (Q1 2024: $112 million

      4/22/25 4:17:09 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Completes Acquisition of RLS (USA) Inc.

      MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals. The acquisition immediately enhances Telix's presence in the United States (U.S.), with a network of over 30 radiopharmacies3 dispensing radiopharmaceuticals manufactured by Telix and other companies, while bringing a team of highly-skilled and multi-disciplinary radiopharmaceutical professionals into the Company. Th

      1/27/25 4:43:43 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care